Monopar Therapeutics Inc.

NASDAQ:MNPR

Biotechnology

Healthcare
$70.75 +2.45%

+$1.58 today

Market cap
$479.46M
Beta
1.54
P/E (TTM)
-37.6
EPS (TTM)
-$1.76
52W Low $29.18High $105.00

Volume 0.10M

Average 0.17M

MNPR Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

Monopar Therapeutics Inc.NASDAQ: MNPR

Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026

Stock-based compensation grows, but more slowly than its trailing trend

Q1 FY2026 stock-based compensation of $1.69M rose 24.9% year over year, behind the +87.9% change in trailing-twelve-month stock-based compensation. Over 3 fiscal years it compounded at +43.4% a year.

Context

  • Stock-based compensation increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +24.9% toward the trailing-twelve-month pace of +87.9%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$1.69M— QoQ
Last fiscal yearDec 2025
$4.84M+324.1% YoY
LTMMar 2026
$4.07M+87.9% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+24.9%——
1 year+324.1%——
3-year CAGR+43.4%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
4.84M USD
Year-over-year change
+324.1%
4-year CAGR
+34.7%

Stock-Based Compensation vs competitors

How MNPR compares with its peers on the latest reported figures

  • Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +87.9% is the highest of 11, against a peer median of +9.1%.
  • Over three fiscal years its annual growth of +43.4% compares with a peer median of +6.9%.
MNPR Competitors
Stock-Based Compensation for MNPR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
XNCRXencor, Inc.LTM Jun 2026$39.03M USD+10.2%-4.0%37.2%
ZYMEZymeworks Inc.LTM Sep 2026$37.94M USD+56.7%+91.1%14.3%
IMNMImmunome, Inc.LTM Sep 2026$37.41M USD+60.8%+68.9%—
ADCTADC Therapeutics S.A.LTM Mar 2026$12.63M USD+26.4%-48.5%16.0%
MGNXMacroGenics, Inc.LTM Mar 2026$12.55M USD-55.6%-11.3%8.0%
CMPXCompass Therapeutics, Inc.LTM Mar 2026$10.93M USD+20.5%+16.2%—
ALXOALX Oncology Holdings Inc.LTM Mar 2026$9.87M USD-60.9%-19.2%—
IPHAInnate Pharma S.A.FY2025€4.26M EUR+7.9%+0.1%152.7%
MNPRMonopar Therapeutics Inc.LTM Mar 2026$4.07M USD+87.9%+43.4%—
BCYCBicycle Therapeutics plcLTM Mar 2026$2.68M USD-107.0%+13.8%4.2%
ATNMActinium Pharmaceuticals, Inc.LTM Jun 2026$237K USD-98.0%+48.7%0.7%
Peer median (excluding MNPR) —+9.1%+6.9%14.3%

Competitors are the stored peer set for MNPR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(9.1M)(10.52M)(8.4M)(15.59M)(13.72M)
Depreciation & Amortization00000
Deferred Income Tax00000
Stock-Based Compensation1.47M1.64M1.9M1.14M4.84M
Change in Working Capital317.77K1.65M(1.35M)3.49M(2.61M)
Accounts Receivables00000
Inventory00000
Accounts Payables403.97K1.48M(1.33M)506.79K388.22K
Other Working Capital(86.2K)167.52K(20.41K)2.98M(2.99M)
Other Non-Cash Items0004.55M(716.46K)
Operating Cash Flow(7.32M)(7.23M)(7.86M)(6.4M)(12.2M)
Capital Expenditures10000
Acquisitions (Net)00000
Purchases of Investments0(4.92M)(7.88M)(15.32M)(87.15M)
Sales of Investments0012.81M985.73K23.7M
Other Investing Activities00000
Investing Cash Flow0(4.92M)4.93M(14.34M)(63.45M)
Debt Repayment00000
Common Stock Issued10.93M109.34K2.07M59.4M127.71M
Common Stock Repurchased0000(35M)
Dividends Paid00000
Other Financing Activities(45.78K)(76.46K)(46.97K)(104.14K)(1.13M)
Financing Cash Flow10.88M32.87K2.03M59.29M91.57M
Effect of Forex Changes4.62K(3.48K)(16.8K)49497.27K
Net Change in Cash3.57M(12.12M)(920.11K)38.55M16.02M
Free Cash Flow(7.32M)(7.23M)(7.86M)(6.4M)(12.2M)

Monopar Therapeutics Inc.

NASDAQ:MNPR

Intrinsic Alpha fair value

Locked

Current Price

$70.75

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.